CDC FluView is back, and our fears look like reality.
50.8% of circulating H3N2 viruses belong to the 2a.3a.1-K subclade, which have 2 mutations in a very important antigenic site. Our own 2025-2026 vaccine immunogenicity data will be posted in the next couple of weeks.
www.cdc.gov/fluview/surv...
50.8% of circulating H3N2 viruses belong to the 2a.3a.1-K subclade, which have 2 mutations in a very important antigenic site. Our own 2025-2026 vaccine immunogenicity data will be posted in the next couple of weeks.
www.cdc.gov/fluview/surv...
Weekly US Influenza Surveillance Report: Key Updates for Week 45, ending November 8, 2025
Seasonal influenza activity is low.
www.cdc.gov
November 14, 2025 at 8:33 PM
CDC FluView is back, and our fears look like reality.
50.8% of circulating H3N2 viruses belong to the 2a.3a.1-K subclade, which have 2 mutations in a very important antigenic site. Our own 2025-2026 vaccine immunogenicity data will be posted in the next couple of weeks.
www.cdc.gov/fluview/surv...
50.8% of circulating H3N2 viruses belong to the 2a.3a.1-K subclade, which have 2 mutations in a very important antigenic site. Our own 2025-2026 vaccine immunogenicity data will be posted in the next couple of weeks.
www.cdc.gov/fluview/surv...
Clinical trials and real-world studies demonstrate that biosimilars have comparable safety, efficacy, and immunogenicity to their originators, and switching between them is safe.
November 14, 2025 at 12:35 PM
Clinical trials and real-world studies demonstrate that biosimilars have comparable safety, efficacy, and immunogenicity to their originators, and switching between them is safe.
as they efficiently induce cellular immunity & provide cross-immunogenicity against various antigenic subtypes…
journals.asm.org/doi/10.1128/...
journals.asm.org/doi/10.1128/...
Live-attenuated influenza virus vaccine strain with an engineered temperature-sensitive and genetically stable viral polymerase variant | Journal of Virology
Influenza virus elicits respiratory tract disease and is a threat to global human
health. Vaccination is considered an effective tool for reducing the morbidity and
mortality caused by influenza disea...
journals.asm.org
November 14, 2025 at 6:58 AM
as they efficiently induce cellular immunity & provide cross-immunogenicity against various antigenic subtypes…
journals.asm.org/doi/10.1128/...
journals.asm.org/doi/10.1128/...
Now listening to Dr Mitra Ashayeripanah sharing their approach to develop more immunogenic bacille Calmette-Guerin (BCG) strains for vaccination: "Enhanced immunogenicity in mouse by recombinant BCG prime and protein boost based on latency antigen Rv1733c and/or reactivation antigen RpfE".
November 14, 2025 at 1:16 AM
Now listening to Dr Mitra Ashayeripanah sharing their approach to develop more immunogenic bacille Calmette-Guerin (BCG) strains for vaccination: "Enhanced immunogenicity in mouse by recombinant BCG prime and protein boost based on latency antigen Rv1733c and/or reactivation antigen RpfE".
This prospective observational study evaluated the immunogenicity of the Heplisav-B vaccine in 85 adult patients with inflammatory bowel disease (IBD) who were not previously seroprotected against hepatitis B.
November 13, 2025 at 4:48 PM
This prospective observational study evaluated the immunogenicity of the Heplisav-B vaccine in 85 adult patients with inflammatory bowel disease (IBD) who were not previously seroprotected against hepatitis B.
#JustPublished in @lancetgh.bsky.social: results from a Phase 3 clinical trial of #EuBiologics’ typhoid conjugate vaccine. The vaccine demonstrates strong safety & immunogenicity—a crucial step toward a sustainable supply of lifesaving typhoid vaccine. https://bit.ly/47HyvVe
#TakeOnTyphoid
#TakeOnTyphoid
EuTYPH-C Inj.® Multi-dose demonstrates strong safety and immunogenicity: Results now available from a Phase 3 study
bit.ly
November 13, 2025 at 2:35 PM
#JustPublished in @lancetgh.bsky.social: results from a Phase 3 clinical trial of #EuBiologics’ typhoid conjugate vaccine. The vaccine demonstrates strong safety & immunogenicity—a crucial step toward a sustainable supply of lifesaving typhoid vaccine. https://bit.ly/47HyvVe
#TakeOnTyphoid
#TakeOnTyphoid
📚MedChemExpress Digest | #LNPs
Lipid nanoparticles enable efficient delivery of nucleic acids via endocytosis and endosomal escape.💡Key advantages:
• Low immunogenicity&high biocompatibility
• Strong stability&transfection efficiency
• Potent endosomal escape
#DrugDelivery
Lipid nanoparticles enable efficient delivery of nucleic acids via endocytosis and endosomal escape.💡Key advantages:
• Low immunogenicity&high biocompatibility
• Strong stability&transfection efficiency
• Potent endosomal escape
#DrugDelivery
November 13, 2025 at 3:18 AM
📚MedChemExpress Digest | #LNPs
Lipid nanoparticles enable efficient delivery of nucleic acids via endocytosis and endosomal escape.💡Key advantages:
• Low immunogenicity&high biocompatibility
• Strong stability&transfection efficiency
• Potent endosomal escape
#DrugDelivery
Lipid nanoparticles enable efficient delivery of nucleic acids via endocytosis and endosomal escape.💡Key advantages:
• Low immunogenicity&high biocompatibility
• Strong stability&transfection efficiency
• Potent endosomal escape
#DrugDelivery
Longer PMPC chains reduced immunological phagocytosis, extended plasma half-life, lowered immunogenicity, and improved therapeutic outcomes compared to native protein and shorter-chain conjugates.
November 13, 2025 at 12:23 AM
Longer PMPC chains reduced immunological phagocytosis, extended plasma half-life, lowered immunogenicity, and improved therapeutic outcomes compared to native protein and shorter-chain conjugates.
In a phase 1 trial in the United States and Liberia, a replication-competent recombinant vesicular stomatitis virus–vectored vaccine against Lassa fever had acceptable safety and was immunogenic over a wide dose range. Full trial results and Research Summary: nej.md/47pstZ9
#MedSky
#MedSky
November 12, 2025 at 2:09 PM
In a phase 1 trial in the United States and Liberia, a replication-competent recombinant vesicular stomatitis virus–vectored vaccine against Lassa fever had acceptable safety and was immunogenic over a wide dose range. Full trial results and Research Summary: nej.md/47pstZ9
#MedSky
#MedSky
ChAdOx1 RVF vaccine showed safety, tolerability, and immunogenicity in healthy adults, inducing immunity. Further studies on 5·0×10^10 dose in diverse populations are needed.##idsky
[Articles] Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
A single dose of ChAdOx1 RVF vaccine seemed to be safe, tolerable, and immunogenic in healthy adults in an RVF-endemic setting, eliciting humoral and cellular immunity. Further evaluation of the 5·0 × 1010 dose in larger and more diverse populations in areas susceptible to outbreaks is warranted.
www.thelancet.com
November 12, 2025 at 12:00 PM
ChAdOx1 RVF vaccine showed safety, tolerability, and immunogenicity in healthy adults, inducing immunity. Further studies on 5·0×10^10 dose in diverse populations are needed.##idsky
New Research
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
www.thelancet.com/journals/lan...
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
www.thelancet.com/journals/lan...
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escala...
A single dose of ChAdOx1 RVF vaccine seemed to be safe, tolerable, and immunogenic
in healthy adults in an RVF-endemic setting, eliciting humoral and cellular immunity.
Further evaluation of the 5·0 ×...
www.thelancet.com
November 12, 2025 at 9:01 AM
New Research
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
www.thelancet.com/journals/lan...
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
www.thelancet.com/journals/lan...
TEIP: A Compact, Open-Source Framework for Predicting Tumor Epitope Immunogenicity in Glioblastoma Cancer Using Deep Learning and Multi-Modal Biological Features https://www.biorxiv.org/content/10.1101/2025.11.09.687510v1
November 11, 2025 at 11:00 PM
TEIP: A Compact, Open-Source Framework for Predicting Tumor Epitope Immunogenicity in Glioblastoma Cancer Using Deep Learning and Multi-Modal Biological Features https://www.biorxiv.org/content/10.1101/2025.11.09.687510v1
TEIP: A Compact, Open-Source Framework for Predicting Tumor Epitope Immunogenicity in Glioblastoma Cancer Using Deep Learning and Multi-Modal Biological Features https://www.biorxiv.org/content/10.1101/2025.11.09.687510v1
November 11, 2025 at 11:00 PM
TEIP: A Compact, Open-Source Framework for Predicting Tumor Epitope Immunogenicity in Glioblastoma Cancer Using Deep Learning and Multi-Modal Biological Features https://www.biorxiv.org/content/10.1101/2025.11.09.687510v1
Comparative analysis of adenovirus, mRNA, and protein vaccines reveals context-dependent immunogenicity and efficacy @insight.jci.org @harvardmed.bsky.social
insight.jci.org/articles/vie...
insight.jci.org/articles/vie...
November 11, 2025 at 5:05 PM
Comparative analysis of adenovirus, mRNA, and protein vaccines reveals context-dependent immunogenicity and efficacy @insight.jci.org @harvardmed.bsky.social
insight.jci.org/articles/vie...
insight.jci.org/articles/vie...
Lassa fever has pandemic potential. However, no vaccines are approved. An rVSV Lassa fever vaccine has been developed, but data on its safety and immunogenicity are limited. Research findings are summarized in a new Quick Take video. nej.md/4nzCYO7
#MedSky #IDSky
#MedSky #IDSky
November 11, 2025 at 5:02 PM
Lassa fever has pandemic potential. However, no vaccines are approved. An rVSV Lassa fever vaccine has been developed, but data on its safety and immunogenicity are limited. Research findings are summarized in a new Quick Take video. nej.md/4nzCYO7
#MedSky #IDSky
#MedSky #IDSky
Phase 1 trial of TSCV shows safety & immunogenicity in 22 healthy adults; targets both typhoidal & non-typhoidal Salmonella. PMID:41062830, Nat Med 2025, @NatureMedicine https://doi.org/10.1038/s41591-025-04003-z #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial | Nature Medicine
In sub-Saharan Africa, typhoidal and non-typhoidal Salmonella (NTS) are leading causes of invasive disease among young children. Trivalent Salmonella conjugate vaccine (TSCV) consists of Vi capsule polysaccharide conjugated to tetanus toxoid and core-plus-O-polysaccharides from the two most prevalent invasive NTS serovars conjugated to flagellin subunits. We conducted a first-in-human, randomized, placebo-controlled, phase 1 trial evaluating the safety and immunogenicity of TSCV. A total of 22 healthy adults aged 18−45 years were randomly allocated to 6.25-µg TSCV (n = 8), 12.5-µg TSCV (n = 10) or placebo (n = 4). The primary objective was the assessment of safety. The co-primary immunogenicity objective was the serum IgG response against the three vaccine polysaccharides and two flagellin carrier proteins. Here we show that TSCV was safe and well tolerated, meeting the prespecified safety endpoints, with the most common solicited symptom being short-lived injection site pain. For each
doi.org
November 11, 2025 at 3:10 AM
Phase 1 trial of TSCV shows safety & immunogenicity in 22 healthy adults; targets both typhoidal & non-typhoidal Salmonella. PMID:41062830, Nat Med 2025, @NatureMedicine https://doi.org/10.1038/s41591-025-04003-z #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
IMO, abundant protein profiling vs lack of immunogenicity in plasma comparisons can show co-adm or single to address Covid-19/ flu protocols. Experimental designs to evaluate morbidities influence across patients can reveal efficiency.
@universityoftokyo.bsky.social
www.biorxiv.org/content/10.1...
@universityoftokyo.bsky.social
www.biorxiv.org/content/10.1...
Integrated Antibody and DIA Based Plasma Proteomics Uncover Temporal Host Responses to SARS CoV 2 Infection
This is a single case longitudinal study in which we monitored antibody responses and plasma proteome dynamics over a 310 day period in a single individual who underwent COVID 19 vaccination and SARS ...
www.biorxiv.org
November 11, 2025 at 2:53 AM
IMO, abundant protein profiling vs lack of immunogenicity in plasma comparisons can show co-adm or single to address Covid-19/ flu protocols. Experimental designs to evaluate morbidities influence across patients can reveal efficiency.
@universityoftokyo.bsky.social
www.biorxiv.org/content/10.1...
@universityoftokyo.bsky.social
www.biorxiv.org/content/10.1...
Safety, tolerability, and immunogenicity of INO-4500, a synthetic #DNA-based #vaccine against #Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults, etidiohnew.blogspot.com/2025/11/safe...
Safety, tolerability, and immunogenicity of INO-4500, a synthetic #DNA-based #vaccine against #Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults
etidiohnew.blogspot.com
November 10, 2025 at 4:38 PM
Safety, tolerability, and immunogenicity of INO-4500, a synthetic #DNA-based #vaccine against #Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults, etidiohnew.blogspot.com/2025/11/safe...
New Research
Immunogenicity and safety of an 18-month booster dose
of the VLA15 Lyme borreliosis vaccine candidate after primary
immunisation in children, adolescents, and adults in the USA:
a randomised, observer-blind, placebo-controlled, phase 2 trial
www.thelancet.com/journals/lan...
Immunogenicity and safety of an 18-month booster dose
of the VLA15 Lyme borreliosis vaccine candidate after primary
immunisation in children, adolescents, and adults in the USA:
a randomised, observer-blind, placebo-controlled, phase 2 trial
www.thelancet.com/journals/lan...
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer...
The safety and robust anamnestic immune responses associated with VLA15 boosting support
its use as a strategy to increase anti-OspA antibody levels before tick season among
children, adolescents, and...
www.thelancet.com
November 9, 2025 at 7:46 PM
New Research
Immunogenicity and safety of an 18-month booster dose
of the VLA15 Lyme borreliosis vaccine candidate after primary
immunisation in children, adolescents, and adults in the USA:
a randomised, observer-blind, placebo-controlled, phase 2 trial
www.thelancet.com/journals/lan...
Immunogenicity and safety of an 18-month booster dose
of the VLA15 Lyme borreliosis vaccine candidate after primary
immunisation in children, adolescents, and adults in the USA:
a randomised, observer-blind, placebo-controlled, phase 2 trial
www.thelancet.com/journals/lan...
It's true that the FDA's limit on the amount of aluminum in [v-------] was based on immunogenicity and not safety data.
But LinkedIn doesn't want you to know that.
Here's an example of how censorship enables government-sanctioned disinformation about the "safety" of [v-------] to prevail. 👇
But LinkedIn doesn't want you to know that.
Here's an example of how censorship enables government-sanctioned disinformation about the "safety" of [v-------] to prevail. 👇
LinkedIn Censors Truth about FDA Limit on Aluminum in Vaccines
The documents from which the regulatory limit for aluminum in vaccines was set were obtained by FOIA. LinkedIn doesn't want you to know.
www.jeremyrhammond.com
November 9, 2025 at 1:10 PM
It's true that the FDA's limit on the amount of aluminum in [v-------] was based on immunogenicity and not safety data.
But LinkedIn doesn't want you to know that.
Here's an example of how censorship enables government-sanctioned disinformation about the "safety" of [v-------] to prevail. 👇
But LinkedIn doesn't want you to know that.
Here's an example of how censorship enables government-sanctioned disinformation about the "safety" of [v-------] to prevail. 👇
Pfizer clinical RWE + HTA will rerate $PFE 30%-immunogenicity proves value
November 7, 2025 at 4:17 PM
Pfizer clinical RWE + HTA will rerate $PFE 30%-immunogenicity proves value
I've been watching $PFE; Pfizer mispriced - vaccine RWE, HTA, immunogenicity. +25% 12m analysi
November 7, 2025 at 12:06 PM
I've been watching $PFE; Pfizer mispriced - vaccine RWE, HTA, immunogenicity. +25% 12m analysi
New PTK7-targeting antibody–drug conjugates (ADCs) use fully human, effector-null antibodies linked to a topoisomerase I inhibitor. Engineered for high stability, bystander effect and low immunogenicity, they overcome prior ADC limits, achieving potent, selective tumor killing with minimal toxicity.
November 7, 2025 at 8:27 AM
New PTK7-targeting antibody–drug conjugates (ADCs) use fully human, effector-null antibodies linked to a topoisomerase I inhibitor. Engineered for high stability, bystander effect and low immunogenicity, they overcome prior ADC limits, achieving potent, selective tumor killing with minimal toxicity.
Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine | New England Journal of Medicine www.nejm.org/doi/10.1056/...
Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine | NEJM
Salmonella enterica serovar Paratyphi A (also known as S. Paratyphi A) is responsible
for more than 2 million cases of enteric fever annually. There are no licensed vaccines
against S. Paratyphi A....
www.nejm.org
November 7, 2025 at 2:23 AM
Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine | New England Journal of Medicine www.nejm.org/doi/10.1056/...
Challenges remain: rapid viral evolution causes antigenic mismatch between circulating strains and stockpiled vaccines, reducing efficacy. Universal vaccines targeting conserved regions like HA stem, M2e, and NP face immunogenicity and safety issues. 7/10
November 6, 2025 at 8:24 PM
Challenges remain: rapid viral evolution causes antigenic mismatch between circulating strains and stockpiled vaccines, reducing efficacy. Universal vaccines targeting conserved regions like HA stem, M2e, and NP face immunogenicity and safety issues. 7/10